Drugs and patents in ATC class C07AG - Alpha and beta blocking agents

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
NORMOZIDE	hydrochlorothiazide; labetalol hydrochloride
TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride
LABETALOL HYDROCHLORIDE	labetalol hydrochloride
NORMODYNE	labetalol hydrochloride
TRANDATE	labetalol hydrochloride
>Tradename	>Generic Name

Last updated: June 25, 2026

ATC C07AG (“alpha and beta blocking agents”) is a small but commercially meaningful segment anchored by carvedilol and related fixed-dose strategies. The patent landscape is dominated by older small-molecule estates that have largely cleared in most markets, shifting competition to generic pricing, incremental formulation patents, and (in select cases) line-extensions rather than true late-cycle new MOAs. Competitive pressure is highest where originator brands lost reference protection, and where regulatory exclusivity is not tied to a still-patented NDA/ANDA formulation.

Which alpha and beta blockers are the main ATC C07AG commercial products?

ATC C07AG’s “alpha and beta blocking agents” class is overwhelmingly led by carvedilol-based therapies, with product differentiation driven by formulation (immediate vs controlled-release), dosing convenience, and combination products rather than new molecular entities.

Core active ingredient: carvedilol

Carvedilol is a non-selective beta-blocker with alpha-1 blocking activity.
Common labeled indications in major markets include hypertension, chronic heart failure, and post-myocardial infarction management (depending on label and region).
Commercial structure: originator-to-generic transition is largely complete in major geographies for standard immediate-release carvedilol, while extended-release and combination products are where residual IP and regulatory exclusivities may remain relevant.

Key formulation/dosing vectors that affect patentability

Immediate-release tablets (generic-heavy).
Extended-release formulations (often more IP-protected via formulation/method patents).
Fixed-dose combination tablets where included with other cardiovascular agents (new patent opportunities for combination, dosing regimens, and manufacturing).

What patents protect carvedilol and other alpha-beta blockers (C07AG)?

Patent coverage typically falls into four buckets:

Composition of matter (early, now mostly expired for older carvedilol families in many jurisdictions).
Formulations and solid-state variants (polymorphs, hydrates, particle size distributions, coatings, release profiles).
Methods of manufacturing (process parameters, granulation and compression controls, milling and crystallization).
Method-of-use and dosing regimens (label-expanding or subpopulation claims, titration schemes, CHF maintenance strategies).

Patent types that still matter for generics

Even when the active ingredient composition patents expire, generics can be blocked by:

Product-specific formulation patents (e.g., controlled release).
Process patents (manufacturing steps and critical process parameters).
Packaging/administration patents (less common, but can exist for dosage forms requiring special handling).
Method-of-use patents tied to a still-commercially relevant labeled regimen.

Where Orange Book and generic challenges usually concentrate

For small molecules like carvedilol, the highest-value litigation and risk is normally associated with:

Brand-owned formulation NDA supplements.
Listed patents covering a specific strength, release profile, or manufacturing process for a particular product (not the underlying drug substance).

When does patent exclusivity end for alpha and beta blockers like carvedilol?

For ATC C07AG, the timing answer is product-specific, but the market pattern is consistent:

Primary composition-of-matter for carvedilol-originator families is generally well past active exclusivity periods in major jurisdictions.
Residual protection tends to come from later-cycle patents for specific formulations, delivery systems, or manufacturing processes.
Regulatory exclusivity (e.g., New Chemical Entity or New Drug Product exclusivity) is typically not the binding constraint for carvedilol now; the practical gating item is the listing of patents tied to specific commercial products (Orange Book listings in the US, equivalent national listing systems elsewhere).

Exclusivity timelines that shape market entry

A generic entry plan usually tracks four clocks:

Patent expiration for the relevant listed patents.
Regulatory exclusivity window tied to the specific NDA product (often shorter now for legacy carvedilol).
Pediatric exclusivity extensions (if any) tied to specific patents and jurisdictions.
Litigation and settlement-driven “design around” delays (Paragraph IV outcomes and end-of-case injunctions).

What generic entry risks exist for ATC C07AG products?

Generic risk is driven by whether a brand has:

Listed patents covering the exact generic target (same active, same dosage form, overlapping release profile).
Pending or active litigation around those patents.
Settlement agreements that impose market entry launch caps.

Paragraph IV risk drivers in small-molecule beta-blockers

Common risk points for carvedilol and similar products:

A brand lists formulation or manufacturing patents for a controlled-release or specific strength that the generic must address.
The brand asserts claims in a way that still reads on the generic formulation design (even if generic uses a different process, claim scope may cover the end product characteristics).
Settlement terms delay launch beyond the “paper” expiration date, via authorized generic carve-outs or “no-landing” provisions.

How strong is the patent estate for alpha and beta blockers (C07AG)?

Strength is usually moderate-to-low on the core active ingredient but can be high for specific branded formulations that received later-life patents.

Estate concentration pattern

Broad, early composition-of-matter protection has largely dissipated.
Late-life patenting is often narrower, sometimes limited to:
- Controlled-release drug-device characteristics for specific products.
- A specific polymorph or crystal form.
- A manufacturing process step that must be replicated or differs enough to avoid literal infringement but can still hit doctrine-of-equivalents arguments depending on claim structure.

Litigation-driven view of strength

For assessment and investment decisions, the most actionable metric is not raw patent count but:

Whether patents are Orange Book-listed for the marketed NDC(s).
Whether they have been asserted in litigation.
Whether settlements exist that show defendants agreed to delay.

What patent litigation affects carvedilol and other C07AG drugs?

ATC C07AG litigation is typically less visible than oncology and specialty areas, but it is structurally predictable in small-molecule markets:

Brand sues ANDA filers (Paragraph IV) for infringement of listed patents.
Settlement is reached in a subset where brand continues to assert formulation or process patents with plausible claim scope.
Litigation is less likely to be transformative if the underlying composition-of-matter is already expired.

What to look for in C07AG litigation

Injunction outcomes: whether courts enjoin a launch until patent expiration.
Claim construction that narrows or broadens the brand’s ability to read on the generic formulation.
Design-around strategies: changes in release kinetics, polymer selection, coating weights, or granulation process.

What formulations are protected for alpha-beta blockers: immediate-release vs controlled-release vs combinations?

Immediate-release (IR) carvedilol

Patent coverage tends to be lighter for straightforward IR tablets after early composition expiration.
Residual protection can remain via:
- Polymorph-specific patents.
- Specific excipient systems tied to stability/solubility and manufacturing reproducibility.
- Method-of-use claims tied to specific CHF titration protocols (less common in late cycles).

Controlled-release (CR) carvedilol

Controlled-release products are where formulation estates often concentrate:

Release profile patents: kinetic modeling, release lag, and dissolution targets.
Matrix technology patents: polymer selection and ratios that drive release behavior.
Manufacturing process patents: blending and compression parameters that achieve target dissolution.

Fixed-dose combinations

Combination tablets are patent-rich because they enable:

Composition claims for the multi-active formulation.
Dosing regimen claims.
Manufacturing and stability claims for the multi-drug compatibility.

What is the Orange Book status of alpha and beta blocking agents like carvedilol?

Orange Book status is product-specific and NDC-specific. In practice for legacy carvedilol:

Many NDCs for standard IR tablets are already supplied by multiple generics, reflecting that the key listed patents are either expired or no longer asserted.
Controlled-release or specific branded strengths are more likely to have active Orange Book listings.

Because the Orange Book is a live listing system that can change by supplement, ANDA approvals, patent additions, and withdrawals, a complete and accurate NDC-by-NDC status mapping requires pulling the current Orange Book listings for each marketed carvedilol product. Without that live listing dataset, a market-usable, definitive Orange Book status table for ATC C07AG cannot be produced here.

Which companies lead generic and branded competition in C07AG?

Branded incumbents

Originators with patented branded formulations historically maintained premium pricing.
Their current market role is shaped by which formulation patents remain active.

Generic ecosystem

Carvedilol’s legacy status makes it a common generic target.
Competitive intensity is high in IR tablets with many authorized suppliers and aggressive pricing.

Where competition dynamics change

Controlled-release and fixed-dose combination products see fewer generic entrants because formulation and manufacturing design-around require additional development and patent clearance.

How does the competitive landscape differ between carvedilol and other alpha-beta blockers in C07AG?

Carvedilol dominates commercial volume. Other alpha-beta blockers in this ATC slot, where present, usually have:

Smaller patient populations or regionally limited adoption.
Less dense patent estates due to fewer late-cycle formulation opportunities, or conversely more residual protection if a newer formulation created later patent families.

In business terms:

Investment in “carve-out” differentiation is more defensible for CR and combination products where patent remaining is more plausible.
IR-only generics face rapid commoditization and lower margins unless there is a manufacturing or cost advantage and a clean patent position.

What FDA pathway risks matter for alpha-beta blockers (ANDAs and 505(b)(2))?

ANDA strategy

For IR carvedilol, ANDA entrants often rely on bioequivalence with minimal formulation change.
For CR and niche strengths, the generic often must match dissolution and release performance closely, increasing development time and raising the risk of non-infringement arguments that fail on equivalency.

505(b)(2) strategy

Where companies pursue 505(b)(2):

They typically rely on a bridging rationale to a referenced carvedilol product.
Patent challenges can shift from product dissolution targets to method-of-use or formulation patents listed on the referenced NDA.

Commercial exposure: how much revenue is at risk from generic entry in C07AG?

Revenue exposure is highest in:

Branded carvedilol formulations that still have active listed patents.
Controlled-release or combination products where fewer generics have launched and switching costs are moderate.

Revenue exposure is lowest when:

The active ingredient is already broadly generic and priced competitively.
The remaining patents are narrow and likely design-aroundable.

Without product-level NDC revenue data and current patent listing status, a precise dollar-risk quantification for the entire class cannot be provided.

Key Takeaways

ATC C07AG is dominated commercially by carvedilol; most core substance protection has aged out, shifting the battle to formulation-specific and manufacturing-method patents.
Generic entry risk is driven less by the active molecule’s early composition patents and more by Orange Book-listed patents for specific NDCs, especially controlled-release and combination strengths.
Litigation tends to cluster around formulation and process claims; settlement-driven launch delays can extend market exclusivity beyond the earliest expiration dates.
The most actionable patent due diligence focus is NDC-specific: claim coverage, remaining term, and whether the patents are actually asserted and currently listed.

FAQs

Do alpha-beta blockers like carvedilol still have active patents in the US even after composition-of-matter expires?
What patent claim types most often block ANDA approvals for controlled-release beta-blockers?
How do Paragraph IV settlements affect generic launch timing for carvedilol products?
Which formulation attributes (dissolution profile, matrix polymer, polymorph) drive infringement for CR versions of carvedilol?
Are fixed-dose alpha-beta blocker combinations more patent-dense than single-agent tablets?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
European Medicines Agency. European Public Assessment Reports (EPAR) and product information. https://www.ema.europa.eu/

Drugs in ATC Class C07AG

Drugs in ATC Class: C07AG - Alpha and beta blocking agents

Market dynamics and patent landscape for ATC C07AG (alpha- and beta-blocking agents): key products, exclusivity timelines, and generic/biosimilar risks